Experiences with
Cyramza8 public posts
(FDA) approved the combination of Cyramza (ramucirumab) and Tarceva (erlotinib) for the first line treatment of advanced NSCLC
The combination Cyramza and Tarceva and being available as a first line targeted therapy option gives patients whose tumors have changes in EGFR a new choice for treatment.
Want to take advantage of all our features? Just log in!
or